Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger Inc (NQ: SDGR )

18.19 +0.20 (+1.11%)
Streaming Delayed Price Updated: 11:17 AM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Schrödinger Reports Strong Fourth Quarter and Full-Year 2023 Financial Results
From Schrödinger
Via Business Wire
Schrödinger to Participate in Upcoming Investor Conferences
From Schrödinger
Via Business Wire
Double Your Money: 3 Growth Stocks to Grab in 2024
The Russell 2000 has risen recently as interest rates have climbed, showing that the Street is now more likely to embrace growth stocks. 
Via InvestorPlace
Key Takeaways From Schrodinger Analyst Ratings
Via Benzinga
Is Schrödinger Stock a Buy Now?
Its groundbreaking work is winning it some powerful fans, but it's still risky. 
Via The Motley Fool
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger Provides Update on Progress Across the Business and Outlines 2024 Development and Operational Goals
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Index Up 26% In December
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. 
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
2024 is going to be a sizzler in the biopharma sector. 
Via The Motley Fool
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event
From Schrödinger
Via Business Wire
Artificial Intelligence in Healthcare: 3 Stocks Transforming the Industry
Companies are applying AI in healthcare, leading to better outcomes and stronger performance for their stocks. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week
If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
From Schrödinger
Via Business Wire
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November
The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
3 Cutting-Edge Biotech Stocks for the Bold Investor
With broader market concerns rising, investors may want to consider the relatively insulated allure of biotech stocks to buy. 
Via InvestorPlace
AI Alert: 3 Healthcare Stocks That Are Investing in Artificial Intelligence
We’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger to Participate in Upcoming Investor Conferences
From Schrödinger
Via Business Wire
3 Top Publicly Traded Companies Leading the AI Revolution
Recent data indicates that AI is already saving companies a great deal of money. Here are three AI stocks to buy to exploit the trend. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
From Schrödinger
Via Business Wire
Schrödinger Reports Third Quarter 2023 Financial Results
From Schrödinger
Via Business Wire
Schrödinger to Host Pipeline Day on December 14, 2023
From Schrödinger
Via Business Wire
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.